Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof
Published in The lancet oncology (01.09.2019)
Published in The lancet oncology (01.09.2019)
Get full text
Journal Article
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Long, Georgina V, Prof, Dummer, Reinhard, Prof, Hamid, Omid, MD, Gajewski, Thomas F, Prof, Caglevic, Christian, MD, Dalle, Stephane, Prof, Arance, Ana, MD, Carlino, Matteo S, PhD, Grob, Jean-Jacques, Prof, Kim, Tae Min, Prof, Demidov, Lev, Prof, Robert, Caroline, Prof, Larkin, James, Prof, Anderson, James R, PhD, Maleski, Janet, BSN, Jones, Mark, MD, Diede, Scott J, MD, Mitchell, Tara C, MD
Published in The lancet oncology (01.08.2019)
Published in The lancet oncology (01.08.2019)
Get full text
Journal Article
Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Ascierto, Paolo A, MD, Arance, Ana, MD, Dutriaux, Caroline, MD, Di Giacomo, Anna Maria, MD, Rutkowski, Piotr, Prof, Del Vecchio, Michele, MD, Gutzmer, Ralf, Prof, Mandala, Mario, MD, Thomas, Luc, Prof, Demidov, Lev, Prof, Garbe, Claus, Prof, Hogg, David, MD, Liszkay, Gabriella, Prof, Queirolo, Paola, MD, Wasserman, Ernesto, MD, Ford, James, MS, Weill, Marine, MSc, Sirulnik, L Andres, MD, Jehl, Valentine, MSc, Bozón, Viviana, MD, Long, Georgina V, Prof, Flaherty, Keith, MD
Published in The lancet oncology (01.04.2017)
Published in The lancet oncology (01.04.2017)
Get full text
Journal Article
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF -mutant metastatic melanoma: a phase 2 double-blind randomised study
Robert, Caroline, Dr, Dummer, Reinhard, Prof, Gutzmer, Ralf, Prof, Lorigan, Paul, MB, Kim, Kevin B, MD, Nyakas, Marta, MD, Arance, Ana, MD, Liszkay, Gabriella, Prof, Schadendorf, Dirk, Prof, Cantarini, Mireille, MBChB, Spencer, Stuart, MSc, Middleton, Mark R, Prof
Published in The lancet oncology (01.07.2013)
Published in The lancet oncology (01.07.2013)
Get full text
Journal Article
Dabrafenib plus trametinib in patients with BRAFV600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Davies, Michael A, Dr, Saiag, Philippe, Prof, Robert, Caroline, Prof, Grob, Jean-Jacques, Prof, Flaherty, Keith T, Prof, Arance, Ana, MD, Chiarion-Sileni, Vanna, MD, Thomas, Luc, Prof, Lesimple, Thierry, MD, Mortier, Laurent, Prof, Moschos, Stergios J, MD, Hogg, David, MD, Márquez-Rodas, Iván, Prof, Del Vecchio, Michele, Prof, Lebbé, Céleste, Prof, Meyer, Nicolas, Prof, Zhang, Ying, PhD, Huang, Yingjie, MD, Mookerjee, Bijoyesh, MD, Long, Georgina V, Prof
Published in The lancet oncology (01.07.2017)
Published in The lancet oncology (01.07.2017)
Get full text
Journal Article
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
Larkin, James, Dr, Del Vecchio, Michele, MD, Ascierto, Paolo A, MD, Krajsova, Ivana, MD, Schachter, Jacob, Prof, Neyns, Bart, MD, Espinosa, Enrique, MD, Garbe, Claus, Prof, Sileni, Vanna Chiarion, MD, Gogas, Helen, MD, Miller, Wilson H, MD, Mandalà, Mario, MD, Hospers, Geke A P, Prof, Arance, Ana, MD, Queirolo, Paola, Prof, Hauschild, Axel, Prof, Brown, Michael P, PhD, Mitchell, Lada, PhD, Veronese, Luisa, MD, Blank, Christian U, Dr
Published in The lancet oncology (01.04.2014)
Published in The lancet oncology (01.04.2014)
Get full text
Journal Article